Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05898256Phase 2Not yet recruiting
- Sponsor
- Guangxi Medical University
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in nasopharyngeal carcinoma (NPC), sponsored by Guangxi Medical University. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05898256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898256.